publication date: Oct. 27, 2017

Dmitrovsky named president of Leidos Biomedical and director of Frederick Lab

By Paul Goldberg

Ethan Dmitrovsky was appointed president Leidos Biomedical Research, Inc. and Laboratory director of the Frederick National Laboratory for Cancer Research.

Dmitrovsky will succeed the current president, David Heimbrook, who will retire.

FNLCR is operated by Leidos Biomedical under an operations and technical support contract from NCI worth up to $400 million-a-year.

In Frederick, Dmitrovsky will lead a team of 2,200 scientists, health professionals, and supporting staff members basic, translational, and clinical science with a focus on cancer, AIDS, and infectious diseases.

“It is a privilege to serve the Frederick National Laboratory for Cancer Research and give back to the National Institutes of Health, where my career began as a physician-scientist,” Dmitrovsky said to The Cancer Letter.

Dmitrovsky is the former provost and executive vice president of MD Anderson Cancer Center. He was brought in to MD Anderson by the institution’s former president Ronald DePinho, who resigned last March (The Cancer Letter, March 9).

Dmitrovsky remained in his administrative positions at MD Anderson through last June, when the cancer center simplified its power structure, eliminating the three executive vice president positions.

At that time, he was moved to on MD Anderson’s Cancer Center Support Grant and returned to his scientific work (The Cancer Letter, June 30).

Dmitrovsky most recently served as the Olga … Continue reading Dmitrovsky named president of Leidos Biomedical and director of Frederick Lab

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.